Meeting
2018 ASCO Annual Meeting
Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.
Authors
Jordan Gauthier
Fred Hutchinson Cancer Research Center, Seattle, WA
Jordan Gauthier , Alexandre V. Hirayama , Kevin Anthony Hay , Daniel Li , Alyssa Sheih , Vicky Wu , Jenna M. Voutsinas , Sindhu Cherian , Xueyan Chen , Barbara S. Pender , Reed M. Hawkins , Aesha Vakil , Tinh-Doan Phi , Rachel N. Steinmetz , Stanley R. Riddell , David G. Maloney , Cameron Turtle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT01865617
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7567)
DOI
10.1200/JCO.2018.36.15_suppl.7567
Abstract #
7567
Poster Bd #
204
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson
Poster
2022 ASCO Annual Meeting
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
First Author: Paolo Strati
Poster
2021 ASCO Annual Meeting
CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
First Author: Jordan Gauthier
Poster
2023 ASCO Annual Meeting
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
First Author: Navin R. Pinto